SCYNEXIS Starts Phase 1 Trial Of SCY-770 Activator Of Two Dosing Regimens
SCYNEXIS, Inc. (NASDAQ: SCYX ), a clinical-stage biotechnology company advancing novel therapies for severe rare diseases, today announced initiation of a Phase 1 study of SCY-770, a first-in-class, potent and direct AMP-activated protein kinase (AMPK) activator. The study will characterize the food-effect and define t